463 reports of this reaction
2.1% of all PIPERACILLIN AND TAZOBACTAM reports
#6 most reported adverse reaction
DRUG INTERACTION is the #6 most commonly reported adverse reaction for PIPERACILLIN AND TAZOBACTAM, manufactured by Apotex Corp.. There are 463 FDA adverse event reports linking PIPERACILLIN AND TAZOBACTAM to DRUG INTERACTION. This represents approximately 2.1% of all 21,987 adverse event reports for this drug.
Patients taking PIPERACILLIN AND TAZOBACTAM who experience drug interaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INTERACTION is a less commonly reported adverse event for PIPERACILLIN AND TAZOBACTAM, but still significant enough to appear in the safety profile.
In addition to drug interaction, the following adverse reactions have been reported for PIPERACILLIN AND TAZOBACTAM:
The following drugs have also been linked to drug interaction in FDA adverse event reports:
DRUG INTERACTION has been reported as an adverse event in 463 FDA reports for PIPERACILLIN AND TAZOBACTAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INTERACTION accounts for approximately 2.1% of all adverse event reports for PIPERACILLIN AND TAZOBACTAM, making it a notable side effect.
If you experience drug interaction while taking PIPERACILLIN AND TAZOBACTAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.